According to a new report published by Introspective Market Research, titled, Neurodegenerative Disease Market by Disease Type, Treatment, and End User, The Global Neurodegenerative Disease Market Size Was Valued at USD 14.72 Billion in 2023 and is Projected to Reach USD 24.22 Billion by 2032, Growing at a CAGR of 5.69% from 2024 to 2032.The neurodegenerative disease market is experiencing steady growth as the global burden of chronic neurological disorders continues to rise. Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), are characterized by progressive deterioration of nerve cells in the brain and spinal cord. These conditions significantly impact patients’ quality of life and place a substantial economic burden on healthcare systems worldwide.
Modern treatment approaches, including disease-modifying therapies, symptomatic treatments, and advanced diagnostic technologies, are driving improvements in patient outcomes compared to traditional care models. Growing awareness, combined with advances in personalized medicine and biomarker research, is encouraging earlier diagnosis and targeted interventions. The market is further supported by strong investments from pharmaceutical companies and research institutions focusing on novel therapeutic options for neurodegenerative conditions.
One of the primary drivers of the neurodegenerative disease market is the increasing prevalence of Alzheimer’s and Parkinson’s diseases among the aging population. Rising life expectancy worldwide has led to a higher incidence of age-related neurological disorders, necessitating advanced treatment and management solutions. Governments and healthcare providers are prioritizing initiatives to strengthen diagnosis, enhance therapeutic options, and provide long-term care, while pharmaceutical companies are investing heavily in R&D to launch new drug formulations and therapies aimed at slowing disease progression.
A key opportunity in the neurodegenerative disease market lies in the development of precision medicine and targeted therapies. Advances in genetics, molecular biology, and biomarker research are paving the way for more personalized treatment approaches tailored to individual patient profiles. Additionally, the growing adoption of digital health technologies, such as AI-powered diagnostic tools and remote monitoring systems, is creating opportunities for improved disease management. These innovations have the potential to significantly expand access to care and transform the market landscape in the coming years.
Neurodegenerative Disease Market, Segmentation
The Neurodegenerative Disease Market is segmented on the basis of Disease Type, Treatment, and End User.
Disease Type Segment
- The disease type segment is further classified into Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, ALS, and Others. Among these, the Alzheimer’s Disease sub-segment accounted for the highest market share in 2023. Alzheimer’s is the most common neurodegenerative condition globally, driven by rising geriatric populations and limited curative treatments. The demand for therapies and supportive care continues to grow, while ongoing research focuses on disease-modifying drugs to slow progression and reduce healthcare burdens.
Treatment Segment
- The treatment segment is further classified into Drugs, Therapies, and Others. Among these, the Drugs sub-segment accounted for the highest market share in 2023. Pharmaceuticals remain the primary option for managing neurodegenerative diseases, helping control symptoms and improve patient quality of life. Increasing availability of generic drugs, alongside a robust pipeline of novel therapies under clinical trials, is driving continued dominance of this segment.
Some of The Leading/Active Market Players Are-
- Biogen Inc. (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- AbbVie Inc. (USA)
- Merck & Co., Inc. (USA)
- Eisai Co., Ltd. (Japan)
- Johnson & Johnson (USA)
- UCB S.A. (Belgium)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Lundbeck A/S (Denmark)
- Amgen Inc. (USA)
- GlaxoSmithKline plc (UK)
- Takeda Pharmaceutical Company Limited (Japan)
- Sun Pharmaceutical Industries Ltd. (India)
and other active players.
Key Industry Developments
- In March 2024, Biogen announced the expansion of its Alzheimer’s drug portfolio with the launch of an innovative treatment aimed at slowing disease progression.
The new therapy, supported by positive clinical trial data, reflects Biogen’s continued commitment to addressing unmet needs in neurodegenerative diseases. - In July 2024, Roche entered into a strategic collaboration with a leading AI-healthtech firm to enhance early detection and monitoring of Parkinson’s disease.
The partnership focuses on integrating digital biomarkers and AI-driven analytics into patient care, accelerating the adoption of precision medicine approaches.
Key Findings of the Study
- Alzheimer’s disease dominated the disease type segment in 2023.
- Drugs accounted for the largest treatment share.
- North America led the global market due to advanced healthcare infrastructure.
- Aging population and rising neurological cases drive growth.
- Precision medicine and digital health integration are key future trends.
